Plecanatide

• CAT Number: I034876
• CAS Number: 467426-54-6
• Molecular Formula: C65H104N18O26S4
• Molecular Weight: 1681.89
• Purity: 98%
• Synonyms: Plecanatide; SP-304; SP 304; SP304; Trulance
• Target: Guanylate Cyclase
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃for long term (months to years).
• IUPAC Name: L-asparaginyl-L-alpha-aspartyl-L-alpha-glutamyl-L-cysteinyl-L-alpha-Glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-leucine cyclic (4→12),(7→15)-bis(disulfide)
• InChI: InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1
• InChIKey: NSPHQWLKCGGCQR-DLJDZFDSSA-N
• SMILES: CC(C)C[C@H](NC([C@H]1NC(CNC([C@@H](NC([C@H]2NC([C@H](C)NC([C@@H](NC([C@H](CC(N)=O)NC([C@@H](NC([C@H](CSSC1)NC([C@H](CC(C)C)NC([C@H](CCC(O)=O)NC([C@H](CSSC2)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@@H](N)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)C(C)C)=O)=O)C(C)C)=O)=O)=O)[C@@H](C)O)=O)=O)=O)C(O)=O

Plecanatide (Cat.No:I034876) is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP).

Reference

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548762/ PubMed PMID: 31644071.
2: Bassotti G, Usai Satta P, Bellini M. Plecanatide for the treatment of chronic idiopathic constipation in adult patients. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1019-1026. doi: 10.1080/17512433.2019.1670057. Epub 2019 Oct 1. Review. PubMed PMID: 31575291.
3: Sharma A, Herekar AA, Bhagatwala J, Rao SS. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy. Clin Exp Gastroenterol. 2019 Jan 22;12:31-36. doi: 10.2147/CEG.S145668. eCollection 2019. Review. PubMed PMID: 30774407; PubMed Central PMCID: PMC6348976.
4: Miner PB Jr. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation. Drug Saf. 2019 May;42(5):603-615. doi: 10.1007/s40264-018-0781-9. Review. PubMed PMID: 30649746.
5: Love BL. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome. Am J Med. 2019 May;132(5):572-575. doi: 10.1016/j.amjmed.2018.11.027. Epub 2018 Dec 11. Review. PubMed PMID: 30550753.
6: Islam BN, Sharman SK, Browning DD. Clinical utility of plecanatide in the treatment of chronic idiopathic constipation. Int J Gen Med. 2018 Aug 10;11:323-330. doi: 10.2147/IJGM.S125051. eCollection 2018. Review. PubMed PMID: 30127634; PubMed Central PMCID: PMC6089121.
7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK513065/ PubMed PMID: 30000995.
8: Martinez de Andino N. Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide. J Am Assoc Nurse Pract. 2018 Jul;30(7):412-420. doi: 10.1097/JXX.0000000000000090. Review. PubMed PMID: 29979299.
9: Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2018 Jun 8;11:1756284818777945. doi: 10.1177/1756284818777945. eCollection 2018. Review. PubMed PMID: 29942351; PubMed Central PMCID: PMC6009086.
10: Miner PB Jr. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2018 Feb;19(2):177-183. doi: 10.1080/14656566.2018.1427733. Epub 2018 Jan 29. Review. PubMed PMID: 29376436.
11: Al-Salama ZT, Syed YY. Plecanatide: First Global Approval. Drugs. 2017 Apr;77(5):593-598. doi: 10.1007/s40265-017-0718-0. Review. PubMed PMID: 28255961.